BrainsWay Financial Performance Overview
BrainsWay Ltd. (NASDAQ: BWAY) has posted impressive financial results for the third quarter of 2025, showcasing a remarkable 29% increase in revenue, amounting to $13.5 million when compared to the third quarter of 2024. This growth reflects the continuous demand for BrainsWay's advanced noninvasive neurostimulation treatments, establishing the company as a leader in mental health solutions.
Operational Highlights
Revenue and Profit Growth
The operating income for the quarter reached $1.3 million, a significant rise from $0.3 million in the previous year. Furthermore, the company achieved an adjusted EBITDA of approximately $2 million, nearly 80% higher than the $1.1 million reported in the third quarter of the previous year. BrainsWay's net profit also experienced exponential growth by 137%, totaling $1.6 million.
Customer Engagement and Market Expansion
Approximately 70% of recent customer engagements have transitioned to multi-year lease agreements, indicating stronger customer loyalty and commitment to BrainsWay's innovative Deep TMS™ technology. Currently, the company holds $65 million in remaining performance obligations from these multi-year contracts, providing a solid foundation for future revenue generation.
Technological Advancements in Treatment Protocols
FDA Approvals
In a huge advancement for the company, the U.S. Food and Drug Administration has cleared BrainsWay's accelerated protocol for the treatment of Major Depressive Disorder (MDD). This FDA clearance allows for a faster implementation of treatments, potentially reaching more patients in need of effective mental health solutions.
Funding for Research
The company has also received a $2.5 million grant from the National Institutes of Health (NIH) to fund research at Stanford University examining the efficacy of BrainsWay's Deep TMS for the treatment of Alcohol Use Disorder (AUD). This underscores the potential and versatility of their technology in addressing various mental health challenges.
Financial Guidance for 2025
With positive trends continuing, BrainsWay is raising the midpoint of its full-year 2025 revenue guidance to between $51 million and $52 million from the earlier forecast of $50 million to $52 million. Expected operating income is now projected to be in the range of 6% to 7%, which is an update from previous estimates of 4% to 5%. Adjusted EBITDA guidance has also increased to between 13% and 14% from the earlier range of 12% to 13%.
CEO Insights
“Market dynamics continue to align in our favor as we maintained strong top-line growth and increased profitability. Our Deep TMS system drove record demand in the third quarter of 2025, with meaningful adoption among both existing and new customers. Looking ahead, we see significant opportunities to extend our leadership through new therapeutic indications and accelerated treatment protocols,” said Hadar Levy, BrainsWay's Chief Executive Officer.
Strategic Investments
In addition to these accomplishments, BrainsWay has made four strategic minority equity investments in 2025, enhancing its position within the mental health treatment ecosystem. A notable investment includes an initial $5 million in Neurolief Ltd., which focuses on developing wearable brain neuromodulation technology for home use.
Conference Call Details
BrainsWay's management has scheduled a conference call to discuss these recent developments. Interested parties are encouraged to join the live call to gain further insights into the company's financial performance and strategic plans.
Frequently Asked Questions
What was BrainsWay's revenue growth in Q3 2025?
BrainsWay reported a revenue increase of 29% to $13.5 million in Q3 2025 compared to the same period in 2024.
How much did BrainsWay's net profit increase in Q3 2025?
The company’s net profit for Q3 2025 increased by 137%, totaling $1.6 million.
What significant FDA approval did BrainsWay receive?
BrainsWay received FDA clearance for an accelerated treatment protocol for Major Depressive Disorder (MDD).
What is the financial guidance for BrainsWay in 2025?
For 2025, BrainsWay is guiding for revenues of $51 million to $52 million and an adjusted EBITDA of 13% to 14%.
What new investments has BrainsWay made?
In 2025, BrainsWay made multiple minority equity investments, including a $5 million strategic investment in Neurolief Ltd., focusing on innovative neuromodulation solutions.
